{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:09:05Z","timestamp":1793862545480,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.05.062","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T17:54:33Z","timestamp":1591811673000},"page":"5851-5860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Two decades of vaccine innovations for global public good: Report of the Developing Countries\u2019 Vaccine Manufacturers Network 20th meeting, 21\u201323 october 2019, Rio de Janeiro, Brazil"],"prefix":"10.1016","volume":"38","author":[{"given":"Sonia","family":"Pagliusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Dennehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.05.062_b0005","unstructured":"World Health Organization. Immunisation Agenda 2030. A Global Strategy To Leave No One Behind. 2019:1\u201329. https:\/\/www.who.int\/immunization\/sage\/meetings\/2019\/october\/2_ia2030_SAGE_submission.pdf [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0010","unstructured":"United Nations. Sustainable Development Goals. https:\/\/www.un.org\/sustainabledevelopment\/sustainable-development-goals\/ [accessed May 12, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0015","unstructured":"World Health Organization. A world at risk. Annual report on global preparedness for health emergencies. 2019:1\u201348. https:\/\/apps.who.int\/gpmb\/assets\/annual_report\/GPMB_annualreport_2019.pdf [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0020","unstructured":"PATH. Centre for vaccine innovation and access. https:\/\/www.path.org\/programs\/center-for-vaccine-innovation-and-access\/ [accessed May 12, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/d41586-018-07758-3","article-title":"Vaccine candidates for poor nations are going to waste","volume":"564","author":"Kaslow","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.05.062_b0030","unstructured":"World Health Organization. Full Public Health Value Propositions for Vaccines. Executive summary 2018; 1 \u2013 2. https:\/\/www.who.int\/immunization\/sage\/meetings\/2018\/april\/1_WHO_FPHVPExecSum_SAGE_Apr2018.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2020.05.062_b0035","unstructured":"World Health Organization. A global strategy to eliminate yellow fever epidemics (EYE) 2017-2026. 2018:1\u201355. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/272408\/9789241513661-eng.pdf [accessed January 14, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0040","unstructured":"Measles and Rubella Initiative. MRI. https:\/\/measlesrubellainitiative.org\/ [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0045","unstructured":"Pan American Health Organization. Reports of the Technical Advisory Group (TAG) on vaccine-preventable Diseases. https:\/\/www.paho.org\/en\/tag\/final-reports-tag-meetings-vaccine-preventable-diseases."},{"key":"10.1016\/j.vaccine.2020.05.062_b0050","unstructured":"Global polio eradication initiative. GPEI. http:\/\/polioeradication.org\/ [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0055","unstructured":"World Health Organization. Global measles and rubella update 2019. https:\/\/www.who.int\/immunization\/sage\/meetings\/2019\/october\/kretsinger_measlesRubella_sage_october_2019.pdf."},{"key":"10.1016\/j.vaccine.2020.05.062_b0060","unstructured":"World Health Organization. Two out of three wild poliovirus strains eradicated 2019. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/two-out-of-three-wild-poliovirus-strains-eradicated [accessed January 7, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0065","unstructured":"World Health Assembly. Improving the transparency of markets for medicines, vaccines, and other health products 2019:1\u20133. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA72\/A72_ACONF2Rev1-en.pdf [accessed January 7, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0070","unstructured":"World Health Organization. MI4A: Market Information for Access to Vaccines https:\/\/www.who.int\/immunization\/programmes_systems\/procurement\/mi4a\/platform\/en\/ [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0075","unstructured":"Vaccine Procurement Practitioners Network. VPPN. https:\/\/lnct.global\/resources\/vaccine-procurement-practitioners-network\/"},{"key":"10.1016\/j.vaccine.2020.05.062_b0080","unstructured":"Institute for Health Metrics & Evaluation. IHME http:\/\/www.healthdata.org\/ [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0085","unstructured":"Gates Foundation. Bill and Melinda Gates Medical Research Institute https:\/\/www.gatesmri.org\/ [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0090","unstructured":"Right Fund. Right Fund. Research investment for Global Health Technology Fund. http:\/\/www.rightfund.org\/ [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0095","unstructured":"The National Institute for Innovation in Manufacturing Biopharmaceuticals. NIIMBL. https:\/\/niimbl.force.com\/s\/news\/a0a6A000002y0stQAA\/niimbl-launches-global-health-fund [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0100","unstructured":"The National Institute for Innovation in Manufacturing Biopharmaceuticals. Vaccines Roadmap 2018:1\u201328. https:\/\/niimbl.force.com\/s\/niimbl-roadmaps [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0105","unstructured":"The National Institute for Innovation in Manufacturing Biopharmaceuticals. Project call 3.1G Request for proposals 2019. https:\/\/www.niimbl.org\/Downloads\/Project_Call_3-1\/PC3.1G-RequestforProposals-FINAL [accessed January 7, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0110","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.vaccine.2019.03.025","article-title":"Regulatory Experts Working Group. Opportunities for improving access to vaccines in emerging countries through efficient and aligned registration procedures: An industry perspective","volume":"37","author":"Dellepiane","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.062_b0115","unstructured":"World Health Organization. Delivering quality-assured medical products for all 2019-2023: WHO\u2019s five year plan to help build effective and efficient regulatory systems (WHO\/MVP\/RHT\/2019.01). 2019:1\u201335. https:\/\/www.who.int\/medicines\/news\/2019\/WHO_ActionPlanWeb.pdf [accessed January 14, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0120","unstructured":"World Health Organization. Emergency use listing procedure 2018:1\u201346. https:\/\/www.who.int\/immunization_standards\/vaccine_quality\/EUL\/en\/ [accessed January 7, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0125","unstructured":"World Health Organization. Impact assessment of WHO prequalification and systems supporting activities 2019. https:\/\/www.who.int\/medicines\/news\/2019\/report_Impact-assessment_WHO-PQ-Reg-systems.pdf [accessed January 14, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0130","unstructured":"Pan American Network for Drug Regulatory Harmonization. Regulatory reliance principles: Concept note and recommendations. 2018:1\u201314. http:\/\/iris.paho.org\/xmlui\/bitstream\/handle\/123456789\/51549\/PAHOHSS19003_eng.pdf [accessed January 14, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.vaccine.2017.05.012","article-title":"Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination","volume":"36","author":"Perez-Vilar","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.062_b0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.vaccine.2017.04.069","article-title":"Building capacity for active surveillance of vaccine adverse events in the Americas: A hospital-based multi-country network","volume":"36","author":"Bravo-Alc\u00e1ntara","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.062_b0145","unstructured":"World Health Organization Regional Office for Africa. AVAREF tools https:\/\/www.afro.who.int\/publications\/avaref-tools [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0150","unstructured":"World Health Organization. Global Vaccine Safety Blueprint 2.0 (GVSB2.0) 2019:1\u201338. https:\/\/www.who.int\/vaccine_safety\/gvs_blueprint-consultation\/en\/ [accessed January 7, 2020]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0155","unstructured":"World Health Organization. 2019; 1 \u2013 32. https:\/\/www.who.int\/vaccine_safety\/publications\/2019_Landscape_Analysis.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2020.05.062_b0160","unstructured":"Vaccine safety net. VSN https:\/\/www.vaccinesafetynet.org\/vsn\/vaccine-safety-net [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0165","unstructured":"Vax Hub. The Future Vaccine Manufacturing Research Hub: securing the supply of essential vaccines https:\/\/www.ucl.ac.uk\/biochemical-engineering\/research\/research-and-training-centres\/vax-hub [accessed January 7, 2020])."},{"key":"10.1016\/j.vaccine.2020.05.062_b0170","unstructured":"Moderna. Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944). 2019. https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-phase-1-results-first-systemic [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0175","unstructured":"Startupticker.ch. Start of clinical trials for LimmaTech\u2019s Shigella vaccine https:\/\/www.startupticker.ch\/en\/news\/september-2019\/start-of-clinical-trials-for-limmatech-s-shigella-vaccine [accessed December 18, 2019])."},{"key":"10.1016\/j.vaccine.2020.05.062_b0180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/glycob\/cwz044","article-title":"Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate","volume":"29","author":"Ravenscroft","year":"2019","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2020.05.062_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/biot.201970055","article-title":"Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture","volume":"14","author":"Kis","year":"2019","journal-title":"Biotechnol J"},{"issue":"7","key":"10.1016\/j.vaccine.2020.05.062_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/biot.201970055","article-title":"Emerging Technologies for Low\u2010Cost, Rapid Vaccine Manufacture","volume":"14","author":"Kis","year":"2019","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.vaccine.2020.05.062_b0195","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1016\/j.vaccine.2019.03.036","article-title":"How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?","volume":"37","author":"Giersing","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.05.062_b0200","unstructured":"Clinical Trials Registry India. A Phase 1 clinical trial to evaluate safety and effectiveness of ZIKA vaccine in healthy adults. http:\/\/ctri.nic.in\/Clinicaltrials\/advsearch.php [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0205","article-title":"Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial","author":"Qiao","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2020.05.062_b0210","article-title":"Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China","author":"Hu","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.vaccine.2020.05.062_b0215","unstructured":"NIH. A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02494999 [accessed December 18, 2019]."},{"key":"10.1016\/j.vaccine.2020.05.062_b0220","unstructured":"World Health Organization. https:\/\/extranet.who.int\/gavi\/PQ_Web\/Default.aspx."},{"key":"10.1016\/j.vaccine.2020.05.062_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-019-0110-z","article-title":"Recent advances in the production of recombinant glycoconjugate vaccines","volume":"4","author":"Kay","year":"2019","journal-title":"npj Vaccines"},{"issue":"5977","key":"10.1016\/j.vaccine.2020.05.062_b0230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1126\/science.1180346","article-title":"Dysregulated Humoral Immunity to Nontyphoidal Salmonella in HIV-Infected African Adults","volume":"328","author":"MacLennan","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.05.062_b0235","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(11)61752-2","article-title":"Invasive non-typhoidal salmonella disease: An emerging and neglected tropical disease in Africa","volume":"379","author":"Feasey","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.05.062_b0240","unstructured":"Gavi. Gavi announcement: vaccine manufacturer GS1 compliance 2019. https:\/\/www.gavi.org\/sites\/default\/files\/document\/supply-procurement\/Gavi%20Announcement%20-%20Vaccine%20GS1%20Compliance.pdf."},{"key":"10.1016\/j.vaccine.2020.05.062_b0245","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/irv.12027","article-title":"Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: A randomized, active-controlled study","volume":"7","author":"Sheldon","year":"2013","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2020.05.062_b0250","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.vaccine.2016.11.095","article-title":"Exploring new packaging and delivery options for the immunization supply chain","volume":"35","author":"Zehrung","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:56Z","timestamp":1759401956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20307076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":50,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X20307076"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two decades of vaccine innovations for global public good: Report of the Developing Countries\u2019 Vaccine Manufacturers Network 20th meeting, 21\u201323 october 2019, Rio de Janeiro, Brazil","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}